Fulcrum Therapeutics (FULC) Projected to Post Quarterly Earnings on Tuesday

Fulcrum Therapeutics (NASDAQ:FULC) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Fulcrum Therapeutics to post earnings of ($0.28) per share for the quarter.

Fulcrum Therapeutics Stock Down 0.5 %

Shares of FULC opened at $3.69 on Tuesday. The stock has a 50 day moving average price of $4.21 and a 200 day moving average price of $4.88. The company has a market capitalization of $199.04 million, a price-to-earnings ratio of -11.90 and a beta of 2.03. Fulcrum Therapeutics has a 52-week low of $2.86 and a 52-week high of $13.70.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on FULC. Royal Bank of Canada restated a “sector perform” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.33.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.